Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.

Hasson H, Messina E, Merli M, Della Torre L, Morsica G, Bagaglio S, Lazzarin A, Uberti-Foppa C.

Int J Infect Dis. 2014 Dec;29:100-2. doi: 10.1016/j.ijid.2014.08.011. Epub 2014 Oct 24.

2.

Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.

Armignacco O, Andreoni M, Sagnelli E, Puoti M, Bruno R, Gaeta GB, Perno CF, Santantonio TA, Bonfanti P, Bonora S, Borderi M, Castagna A, d'Arminio Monforte A, De Luca A, Grossi P, Guaraldi G, Maggiolo F, Mussini C, Sagnelli C, Tavio M, Torti C, Uberti-Foppa C, Andreoni M, Angarano G, Antinori A, Armignacco O, Carosi G, Chirianni A, Di Perri G, Galli M, Lazzarin A, Rizzardini G, Sagnelli E, Taliani G.

New Microbiol. 2014 Oct;37(4):423-38. Epub 2014 Oct 1.

3.

Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients.

Sagnelli C, Uberti-Foppa C, Galli L, Pasquale G, Coppola N, Albarello L, Doglioni C, Lazzarin A, Sagnelli E.

Braz J Infect Dis. 2014 Mar-Apr;18(2):164-9. doi: 10.1016/j.bjid.2013.06.005. Epub 2013 Oct 25.

4.

Patients' satisfaction with sexual and reproductive health services delivered in HIV clinics across European regions.

Platteau T, Müller MC, Nideröst S, Csepe P, Dedes N, Apers L, Schrooten W, Nöstlinger C; Eurosupport 5 Study Group.

Cent Eur J Public Health. 2013 Sep;21(3):123-7.

PMID:
24344532
5.

Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection.

Sagnelli C, Uberti-Foppa C, Pasquale G, De Pascalis S, Coppola N, Albarello L, Doglioni C, Lazzarin A, Sagnelli E.

Infection. 2013 Oct;41(5):959-67. doi: 10.1007/s15010-013-0502-3. Epub 2013 Jul 10.

PMID:
23839212
6.

Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.

Hasson H, Merli M, Galli L, Gallotta G, Carbone A, Messina E, Bagaglio S, Morsica G, Salpietro S, Castagna A, Lazzarin A, Uberti-Foppa C.

Liver Int. 2013 Aug;33(7):1113-20. doi: 10.1111/liv.12159. Epub 2013 Mar 28.

PMID:
23534616
7.

A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.

Brombin C, Diomede L, Tudor D, Drillet AS, Pastori C, Poli E, Riva A, Uberti-Foppa C, Galli M, Di Serio C, Bomsel M, Lopalco L.

PLoS One. 2013;8(3):e58768. doi: 10.1371/journal.pone.0058768. Epub 2013 Mar 22.

8.

Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.

Bagaglio S, Messina E, Uberti-Foppa C, Merli M, Torre LD, Lazzarin A, Hasson H, Morsica G.

J Antimicrob Chemother. 2013 Jun;68(6):1448-50. doi: 10.1093/jac/dkt019. Epub 2013 Feb 6. No abstract available.

9.

HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).

Hasson H, Galli L, Gallotta G, Neri V, Blanc P, D'Annunzio M, Morsica G, Sollima S, Merli M, Lazzarin A, Uberti-Foppa C.

New Microbiol. 2012 Oct;35(4):469-74. Epub 2012 Oct 1.

10.

Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.

Schiavini M, Angeli E, Mainini A, Uberti-Foppa C, Zerbi P, Sagnelli C, Cargnel A, Vago G, Duca PG, Giorgi R, Rizzardini G, Gubertini G.

Hepat Mon. 2011 Jul 1;11(7):525-31.

11.

Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.

Miro JM, Manzardo C, Mussini C, Johnson M, d'Arminio Monforte A, Antinori A, Gill MJ, Sighinolfi L, Uberti-Foppa C, Borghi V, Sabin C; Late Presenters Investigators.

PLoS One. 2011;6(10):e26009. doi: 10.1371/journal.pone.0026009. Epub 2011 Oct 17.

12.

Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.

Morsica G, Bianchi G, Bagaglio S, Conte C, Salpietro S, Porrino L, Uberti-Foppa C.

New Microbiol. 2011 Jul;34(3):317-21. Epub 2011 Jul 30.

13.

Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption.

Bagaglio S, Bianchi G, Danise A, Porrino L, Uberti-Foppa C, Lazzarin A, Castagna A, Morsica G.

Infection. 2011 Apr;39(2):121-6. doi: 10.1007/s15010-011-0093-9. Epub 2011 Mar 22.

PMID:
21424854
14.

Sexual protection behavior in HIV-positive gay men: testing a modified information-motivation-behavioral skills model.

Nöstlinger C, Nideröst S, Platteau T, Müller MC, Staneková D, Gredig D, Roulin C, Rickenbach M, Colebunders R; Swiss HIV Cohort Study and The Eurosupport Study Group.

Arch Sex Behav. 2011 Aug;40(4):817-27. doi: 10.1007/s10508-010-9682-4. Epub 2010 Sep 28.

PMID:
20878223
15.

Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases.

Sagnelli C, Uberti-Foppa C, Galli L, Pasquale G, Coppola N, Albarello L, Masiello A, Doglioni C, Lazzarin A, Sagnelli E.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):107-8. doi: 10.1097/QAI.0b013e3181cf4d8b. No abstract available. Erratum in: J Acquir Immune Defic Syndr. 2010 Jul 1;54(3):338. Galli, Laura [added].

PMID:
20418725
16.

Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.

Bagaglio S, Albarello L, Biswas P, Uberti-Foppa C, Fortis C, Morsica G.

J Med Case Rep. 2009 Nov 9;3:110. doi: 10.1186/1752-1947-3-110.

17.

Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.

Angeli E, Mainini A, Cargnel A, Uberti-Foppa C, Orani A, Carbone R, Andreoni M, Schiavini M, Giorgi R, Rizzardini G, Gubertini G; ICoS-2 Group.

Curr HIV Res. 2009 Jul;7(4):447-55.

PMID:
19601782
18.

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592.

PMID:
19590432
19.

Emotional support and gender in people living with HIV: effects on psychological well-being.

Gordillo V, Fekete E, Platteau T, Antoni MH, Schneiderman N, Nöstlinger C; Eurosupport Study Group.

J Behav Med. 2009 Dec;32(6):523-31. doi: 10.1007/s10865-009-9222-7.

PMID:
19543823
20.

Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.

Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):106-8. doi: 10.1097/QAI.0b013e3181a02fda. No abstract available.

PMID:
19390331
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk